Axol Bioscience acquires ophthalmology business from Newcells Biotech
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
Subscribe To Our Newsletter & Stay Updated